Galderma, L'Oréal, Natura Develop Rapid Weight Loss Skin Care

Global Beauty Firms Target Emerging Market

Major beauty companies, including Swiss firm Galderma, Brazilian group Natura, and French giant L'Oréal, are developing skincare and aesthetic treatments to address facial volume loss and skin laxity. These concerns are increasingly linked to rapid weight reduction, particularly among individuals using GLP-1 weight-loss drugs.

This emerging market for clinical treatments is projected to grow significantly, from US$700 million to US$2 billion over the next five years, according to 2025 estimates by Boston Consulting Group.

The broader obesity drug market, which includes GLP-1 medications like Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Zepbound, is estimated by Pfizer to reach US$150 billion in annual sales by 2030.

Product Development and Clinic Response

Galderma, in which L'Oréal holds a 20% stake, conducted a study in 2025 to evaluate how its existing treatments perform on skin changes associated with GLP-1 weight loss. Anne-Cécile Chevrier, Galderma's global head of injectable aesthetics, noted concerns such as sagginess and hollowness.

The company offers Sculptra, a collagen-stimulating treatment, and Restylane, a hyaluronic acid dermal filler. L'Oréal's chief innovation officer, Delphine Viguier-Hovasse, confirmed the company is conducting separate studies on GLP-1 users.

Similarly, Natura's chief innovation officer, Manuel Krauss, indicated the company is testing existing products and developing new generation treatments, potentially integrating formats like supplements.

A 2024 report by Medical Insight revealed that 53% of US aesthetics clinics anticipate an influx of new patients due to prescription weight-loss medications, with 43% expecting increased demand for related facial treatments.

Expert Views on Causes and Efficacy

Experts clarify that the term "Ozempic face" is misleading, as facial volume loss results from rapid weight reduction rather than a direct effect of GLP-1 drugs themselves. Michael Somenek, a facial plastic surgeon, reported a surge in treatment requests from GLP-1 patients in the past year.

Consultant dermatologist Beibei Du-Harpur emphasized that topical skincare products are unlikely to address volume loss in the fat layer, suggesting injectables are more effective for this specific concern.

Dr. Graeme Glass, a plastic and craniofacial surgeon, added that while creams can improve skin appearance, they cannot alter the face's ligamental structure or reposition deep fat pads. Analysts at KFF also noted that GLP-1 drugs are most widely used by adults aged 50 to 64, an age group already experiencing natural declines in collagen.

Implications for Asia's Beauty Sector

The global trend of addressing skin changes from rapid weight loss presents a significant new category for Asia's beauty industry. As GLP-1 drug adoption continues to expand in affluent Asian markets, demand for specialized aesthetic solutions will likely follow.

Asian cosmetic manufacturers, including OEM/ODM firms, could innovate new formulations or devices tailored to improve skin elasticity and address volume loss. Professional aesthetics clinics across Asia, particularly in markets with advanced medical aesthetics sectors like South Korea, are well-positioned to adapt their service offerings.

This could involve developing new treatment protocols or integrating specific injectables and non-invasive technologies to capture a share of the projected US$2 billion global market for these clinical treatments.